United Therapeutics Buys Thymmune For Up To $300M
By Jade Martinez-Pogue · July 2, 2026, 4:50 PM EDT
Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million....
To view the full article, register now.